Table 1.

Patient Demographics and Cell Manufacturing.^*

Cohort and Patient No.†	Age	Race or Ethnic Group	Sex	Duration of HIV Infection	Baseline CD4 T-Cell Count	Baseline CD4:CD8 T-Cell Ratio	SB-728-T Dose‡	SB-728-T CD3§	SB-728-T Cell Modification	SB-728-T Pentamer Duplication
	yr			yr	per mm3			%	%	per 106 cells
Cohort 1
201	54	White	M	20.2	665	1.38	l.00×l010	97.0	14.6	57,000
203	50	Black	M	21.1	659	0.59	1.08×l010	97.7	24.5	81,000
204	31	White	M	4.3	621	1.43	l.00×l010	97.9	10.9	47,000
205	50	White	M	2.4	955	1.99	l.00×l010	99.1	19.1	64,000
251	56	White	M	23.1	554	1.67	l.00×l010	98.6	14.4	57,000
253	38	Asian	M	2.8	997	0.98	l.00×l010	94.3	18.4	61,000
Median	50			12.3	662	1.41	l.00×l010	97.8	16.5	59,000
Cohort 2
306	50	White	M	19.1	271	0.99	0.77×l010	93.1	20.9	60,000
308	37	Black	M	13.1	328	0.78	0.50×l010	97.5	25.3	67,000
309	48	Asian Indian	F	2.9	341	0.54	0.80×l010	92.3	27.7	67,000
351	60	Black	M	14.1	193	1.25	l.00×l010	97.7	25.4	73,000
354	41	Hispanic	M	15.6	220	0.50	0.90×l010	99.3	26.7	69,000
355	44	Black	F	16.2	272	0.65	l.00×l010	94.1	26.9	72,000
Median	46			14.9	272	0.72	0.85×l010	95.8	26.0	68,000

^*SB-728-T consists of autologous CD4 T cells in which the CCR5 gene was rendered permanently dysfunctional by zinc-finger nucleases.

^†Cohort 1 comprised patients with adequate CD4 T-cell recovery after highly active antiretroviral therapy (HAART), defined as those with CD4 T-cell counts above 450 per cubic millimeter at screening, with a documented nadir of not lower than 300 per cubic millimeter. Cohort 2 comprised patients with inadequate CD4 T-cell recovery after HAART, defined as those with CD4 T-cell counts persistently between 200 per cubic millimeter and 500 per cubic millimeter at screening, despite 2 or more years of HAART.

^‡A single dose of autologous CD4 T cells modified at CCR5 by SB-728-T consisted of an infusion of a median of l.00×l0¹⁰ total cells in cohort 1, and a median of 0.85xl0¹⁰ in cohort 2.

^§The percentages of total cells expressing the T-cell marker CD3 are listed.